Tiglutik (riluzole oral suspension – ITF Pharma) — Cigna

Initial criteria

• Patient has a diagnosis of amyotrophic lateral sclerosis (ALS)
• Medication is prescribed by or in consultation with a neurologist, a neuromuscular disease specialist, or a physician specializing in the treatment of ALS

Approval duration

1 year